Table 1

Baseline characteristics

All patients (n=27)Acute CRT non-responders (n=9)Acute CRT responders (n=18)P value
Age (years)64±968±962±80.09
Male gender (n)21 (78)8 (89)13 (72)0.63
CAD (n)15 (56)5 (56)10 (56)1.0
LV EDV(mL)269±116276±125265±1140.83
LV ESV (mL)199±101197±104200±1020.95
LVIDd (mm)68±970±1267±80.40
LVIDs (mm)61±1062±1360±80.73
LV FS (%)10±512±510±40.19
LV EF (%)28±630±527±70.24
LBBB (n)26 (96)9 (100)17 (94)1.0
QRS width (ms)173±18169±25176±140.39
Q-LV (ms)126±24129±33125±180.69
Intrinsic heart rate (beats per minute)68±863±371±90.01
Intrinsic AV interval (ms)279±47289±53274±440.47
NYHA class II (n)11 (41)3 (33)8 (44)0.69
NYHA class III (n)16 (59)6 (67)10 (56)0.69
ACE inhibitors/ARB (n)27 (100)9 (100)18 (100)1.0
Beta blockers (n)27 (100)9 (100)18 (100)1.0
Aldosterone inhibitors (n)18 (67)6 (67)12 (67)1.0
Loop diuretics (n)20 (74)6 (67)14 (78)0.65
  • ARB, angiotensin receptor blocker; AV, atrioventricular; CAD, coronary artery disease; CRT, cardiac resynchronisation therapy; EDV, end diastolic volume; EF, ejection fraction; ESV, end systolic volume; FS, fraction shortening; LBBB, left bundle branch block; LV, left ventricular; LVIDd, left ventricular internal end diastolic diameter; LVIDs, left ventricular internal end systolic diameter; NYHA, New York Heart Association; Q-LV, time interval from the beginning of QRS to LV sense.